Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs

Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs

– Study conducted using Epigenomics’ Epi proColon(R) 2.0 CE

– Results in line with the results achieved in the CE marking study reported in 2011

– Patient convenience might help to increase early colorectal cancer (CRC) detection especially with non-compliant individuals

Berlin (Germany) and Germantown, MD (U.S.A.), March 5, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced findings from a study executed in different centers in Prague, Pilsen, and Brno. According to the study published in “Vnitř Lék”, a leading Czech journal for internal medicine, in late 2013 blood-based Septin9 testing could be an attractive screening alternative to established methods for a population that would otherwise be non-compliant to colorectal cancer screening. The study was conducted by MU Dr. Zdeněk Beneš, CSc., Head, Medical department of Thomayer Hospital, Prague.

The case control study comprised 57 patients; 33 asymptomatic individuals with negative colonoscopies, and 24 patients with proven adenomas. In this study, Epi proColon(R) 2.0 CE showed a sensitivity of 92% and a specificity of 97%. These results are in line with the results achieved in the CE marking study reported in 2011, which followed the same principle of data interpretation (80% sensitivity and 99% specificity).

According to the authors of the publication, Septin9 testing can be seen as an attractive alternative to existing CRC screening methods in areas where sufficient compliance to CRC screening programs is currently not achieved. Established screening methods, including fecal occult blood testing (FOBT), fecal immunochemical testing (FIT), flexible sigmoidoscopy and colonoscopy are effective and cost-efficient, however, have not reached the effect required based on low patient participation. The benefits of blood-based Septin9 testing over current standard procedures can be seen in the higher convenience for patients given that the test just requires simple blood draw, the non-invasive nature of the test which can be part of routine physician visits and its ability to detect carcinoma independent of its location.

“CRC has a very good prognosis if detected in early stages. Regular screening and early detection of cancers therefore is highly desirable, but screening programs in many countries have very low compliance rates,” commented Dr. Thomas Taapken, CEO/CFO of Epigenomics. “Screening programs based on a convenient blood test have the potential to significantly improve uptake and adherence and ultimately reduce CRC incidence and mortality as well as resulting healthcare cost.”

According to the study, the Czech Republic belongs to the European countries with the highest incidences of colorectal cancer. 94.4 new cases per year are diagnosed in men and 46 in women per 100,000 inhabitants. In the Czech Republic the compliance with a nationwide two-phase screening program based on the detection of occult blood in stool (FOBT) in the asymptomatic population above 50 years was only 22.7% in 2010. Therefore, alternative solutions to improve CRC detection are currently evaluated in the Czech Republic.

– Ends –

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse 1
10178 Berlin
Tel. +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876

pr@epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon^(R), is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. Additionally, the company markets its tissue assay for use in lung cancer diagnosis, Epi proLung^(R), in Europe. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.